MCID: ASP030
MIFTS: 39

Aspirin Resistance

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Aspirin Resistance

MalaCards integrated aliases for Aspirin Resistance:

Name: Aspirin Resistance 56
Aspirin, Resistance to Cardioprotective Effect of 56
Aspirin, Resistance to Antithrombotic Effect of 56
Aspirin Cardioprotective Effect of 56
Aspirin Antithrombotic Effect of 56

Classifications:



External Ids:

OMIM 56 608223

Summaries for Aspirin Resistance

OMIM : 56 Aspirin (acetylsalicylic acid) is a classic nonsteroidal antiinflammatory agent that irreversibly inhibits type I cyclooxygenase (PTGS1, or COX1; 176805) in platelets, resulting in decreased production of thromboxane A2 (TXA2) and inhibition of platelet aggregation. Because of this feature, it is used therapeutically to prevent cardiothrombotic events. Individuals show a variable response to the drug, referred to as aspirin ineffectiveness or resistance, in which not all individuals or populations appear to receive the full prophylactic or therapeutic benefits (summary by Zhou et al., 2011). Halushka and Halushka (2002) discussed a possible basis for resistance to the cardioprotective effect of aspirin. (608223)

MalaCards based summary : Aspirin Resistance, also known as aspirin, resistance to cardioprotective effect of, is related to active peptic ulcer disease and cerebrovascular disease. An important gene associated with Aspirin Resistance is PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Focal Adhesion. The drugs Cilostazol and Dipyridamole have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and kidney, and related phenotypes are homeostasis/metabolism and muscle

Related Diseases for Aspirin Resistance

Diseases related to Aspirin Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 active peptic ulcer disease 29.6 PTGS2 PTGS1
2 cerebrovascular disease 29.3 ITGB3 ITGA2 APOB
3 clopidogrel resistance 29.3 PTGS2 P2RY1 ITGB3
4 thrombosis 28.8 PTGS1 P2RY1 ITGB3 ITGA2
5 vascular disease 28.5 PTGS2 PTGS1 ITGB3 ITGA2 APOB
6 myocardial infarction 28.1 PTGS2 PTGS1 ITGB3 ITGA2 APOB
7 arteries, anomalies of 10.5
8 hyperlipoproteinemia, type iii 10.5
9 lipoprotein quantitative trait locus 10.5
10 ischemia 10.4
11 stroke, ischemic 10.4
12 intermediate coronary syndrome 10.3
13 peripheral vascular disease 10.2
14 heart disease 10.2
15 hypercholesterolemia, familial, 1 10.1
16 gas gangrene 10.1
17 diabetes mellitus 10.1
18 body mass index quantitative trait locus 1 10.1
19 coronary heart disease 1 10.1
20 transient cerebral ischemia 10.1
21 lipid metabolism disorder 10.1
22 kidney papillary necrosis 10.1 PTGS2 PTGS1
23 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0 PTGS2 PTGS1
24 peptic ulcer disease 10.0 PTGS2 PTGS1
25 chronic cystitis 10.0 PTGS2 PTGS1
26 pre-eclampsia 10.0
27 chronic acquired demyelinating polyneuropathy 10.0
28 hydrops, lactic acidosis, and sideroblastic anemia 10.0 PTGS2 PTGS1
29 antenatal bartter syndrome 10.0 PTGS2 PTGS1
30 placental abruption 10.0 PTGS2 PTGS1
31 atherosclerosis susceptibility 10.0
32 angina pectoris 10.0
33 diabetic angiopathy 10.0
34 carotid stenosis 10.0
35 intermittent claudication 10.0
36 kidney disease 10.0
37 gastric ulcer 10.0 PTGS2 PTGS1
38 coronary thrombosis 10.0 PTGS2 ITGB3
39 stomach disease 9.9 PTGS2 PTGS1
40 proteasome-associated autoinflammatory syndrome 1 9.9 PTGS2 PTGS1
41 homocysteinemia 9.9
42 limb ischemia 9.9
43 eclampsia 9.9
44 essential thrombocythemia 9.9
45 coronary stenosis 9.9
46 acute myocardial infarction 9.9
47 blood platelet disease 9.9 PTGS1 ITGB3
48 fetal and neonatal alloimmune thrombocytopenia 9.8 ITGB3 ITGA2
49 angioedema 9.8 PTGS2 PTGS1
50 thrombasthenia 9.7 ITGB3 ITGA2

Graphical network of the top 20 diseases related to Aspirin Resistance:



Diseases related to Aspirin Resistance

Symptoms & Phenotypes for Aspirin Resistance

Clinical features from OMIM:

608223

MGI Mouse Phenotypes related to Aspirin Resistance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 APOB ITGA2 ITGB3 P2RY1 PTGS1 PTGS2
2 muscle MP:0005369 8.92 APOB ITGB3 PTGS1 PTGS2

Drugs & Therapeutics for Aspirin Resistance

Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Dipyridamole Approved Phase 4 58-32-2 3108
3
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
4
Tirofiban Approved Phase 4 144494-65-5 60947
5
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
6
Triflusal Approved, Investigational Phase 4 322-79-2
7
Thrombin Approved, Investigational Phase 4
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
10
Pravastatin Approved Phase 4 81093-37-0 54687
11 Acetylsalicylic acid lysinate Phase 4
12 lysine Phase 4
13 Respiratory System Agents Phase 4
14 Anti-Asthmatic Agents Phase 4
15 Phosphodiesterase Inhibitors Phase 4
16 Phosphodiesterase 3 Inhibitors Phase 4
17 Neuroprotective Agents Phase 4
18 Vasodilator Agents Phase 4
19 Bronchodilator Agents Phase 4
20 Protective Agents Phase 4
21 Aspirin, Dipyridamole Drug Combination Phase 4
22 Immunologic Factors Phase 4
23 Adjuvants, Immunologic Phase 4
24 interferons Phase 4
25 Anti-Infective Agents Phase 4
26 Anti-Bacterial Agents Phase 4
27 Radiation-Protective Agents Phase 4
28 Antiviral Agents Phase 4
29 calcium heparin Phase 4
30 Antibiotics, Antitubercular Phase 4
31 polysaccharide-K Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Lipid Regulating Agents Phase 4
34 Anticholesteremic Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Antimetabolites Phase 4
37 Chinese Salvia Phase 4
38 Calcium, Dietary Phase 4
39
Calcium Nutraceutical Phase 4 7440-70-2 271
40
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
41 Hemostatics Phase 3
42 Gastrointestinal Agents Phase 3
43 Antacids Phase 3
44 Anti-Ulcer Agents Phase 3
45 Proton Pump Inhibitors Phase 3
46 Omega 3 Fatty Acid Phase 1, Phase 2
47
Meloxicam Approved, Vet_approved Phase 1 71125-38-7 54677470 5281106
48 Cyclooxygenase 2 Inhibitors Phase 1
49
Simvastatin Approved 79902-63-9 54454
50 Nutmeg Approved

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients Unknown status NCT01935193 Phase 4 lysine acetylsalicylate
2 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
3 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
4 Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study Unknown status NCT00513149 Phase 4 Clopidogrel
5 Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients Completed NCT00446641 Phase 4 Cilostazol;placebo
6 Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study. Completed NCT00818337 Phase 4 Aspirin
7 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
8 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4 Clopidogrel
9 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
10 Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Completed NCT00398463 Phase 4 Tirofiban;Placebo
11 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
12 Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events Completed NCT02616497 Phase 4 Aspirin;Triflusal
13 Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People Completed NCT00793754 Phase 4 Aspirin;Atorvastatin;Aspirin + Atorvastatin
14 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
15 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
16 Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis Withdrawn NCT01198379 Phase 4 aspirin;Placebo
17 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
18 Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets). Withdrawn NCT01011257 Phase 4 Asprin;Clopidogrel
19 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
20 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00697021 Phase 3 Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg
21 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
22 Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery Completed NCT00330772 Phase 3 Aspirin;Clopidogrel
23 Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B Completed NCT01902498 Phase 2 Aspirin;Aspirin;Aspirin
24 The Effects of Omega-3 Fatty Acids on Aspirin Resistance Completed NCT00771914 Phase 1, Phase 2 Aspirin;Lovaza;Both Aspirin and Lovaza
25 Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery Completed NCT01618006 Phase 2 Aspirin;Aspirin;Aspirin
26 The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes Completed NCT01181882 Phase 2
27 ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial Terminated NCT02326350 Phase 2 Aspirin 75mg;Lactose powder
28 Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance Unknown status NCT01047722 Phase 1 Aspirin ingestion followed by doing a Bleeding Volume Test
29 Mechanism Based Resistance to Aspirin Completed NCT00948987 Phase 1 Aspirin
30 Vascular Damage in Systemic Lupus Erythematosus (SLE) Completed NCT00731302 Phase 1 aspirin and meloxicam
31 Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent Re-occlusion of Cerebral Vessels After Successful Reperfusion. Withdrawn NCT00417898 Phase 1 Aspirin
32 Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient Unknown status NCT01045785
33 Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population Unknown status NCT01408927
34 Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial Unknown status NCT01476020
35 Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure Unknown status NCT00481806
36 Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD) Unknown status NCT01086163 Omacor, omega-3 fatty acids in CAD patients
37 Prevalence of Aspirin Resistance in Hemodialysis Patients Completed NCT00792272
38 Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients Completed NCT01364779
39 Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population Completed NCT01361620 aspirin
40 Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Completed NCT01104441
41 Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients Completed NCT00649909
42 Aspirin Responsiveness in Women With Coronary Artery Disease Completed NCT01406990
43 Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study Completed NCT00389129 acetylsalicylic acid
44 Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease Completed NCT00753935 Early Phase 1 enteric-coated aspirin;Chewable aspirin
45 Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus Completed NCT00563875 acetylsalicylic acid
46 Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel Completed NCT00262275 Aspirin, Clopidogrel
47 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)-A Prospective Multicenter Cohort Study- Completed NCT00250380
48 Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial) Completed NCT03930875
49 The Effect of Serum LDL Lowering on Aspirin Resistance Completed NCT00466154 Aspirin
50 Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance Completed NCT01432652

Search NIH Clinical Center for Aspirin Resistance

Genetic Tests for Aspirin Resistance

Anatomical Context for Aspirin Resistance

MalaCards organs/tissues related to Aspirin Resistance:

40
Testes, Heart, Kidney, Whole Blood, Endothelial, Monocytes

Publications for Aspirin Resistance

Articles related to Aspirin Resistance:

(show top 50) (show all 728)
# Title Authors PMID Year
1
Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. 56 61
21844189 2011
2
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. 61 56
11940542 2002
3
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. 56 61
11472699 2001
4
Development of aspirin resistance in persons with previous ischemic stroke. 56 61
7974569 1994
5
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? 56
11940535 2002
6
One hundred years of aspirin. 56
9259670 1997
7
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. 56
8298418 1994
8
Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. 56
8312766 1994
9
Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. 56
8054013 1994
10
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. 56
1907252 1991
11
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. 56
5284360 1971
12
Aspirin selectively inhibits prostaglandin production in human platelets. 56
5284361 1971
13
Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. 56
13013156 1953
14
Modulation of microRNAs by aspirin in cardiovascular disease. 61
31444100 2020
15
Performance comparison of platelet function analyzers in cardiology patients: VerifyNow and Anysis-200 aspirin assays. 61
32538826 2020
16
Aspirin Resistance Significantly Influences Clinical and Economic Burden in Cardiac Surgery Patients. 61
31586618 2020
17
Prevalence and Clinical Predictors of Aspirin Resistance in Heart Transplant Recipients. 61
32465127 2020
18
Aspirin Resistance Affects Medium-Term Recurrent Vascular Events after Cerebrovascular Incidents: A Three-Year Follow-up Study. 61
32204465 2020
19
Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. 61
32027781 2020
20
Older adults with frailty syndrome present an altered platelet function and an increased level of circulating oxidative stress and mitochondrial dysfunction biomarker GDF-15. 61
31926293 2020
21
[Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology]. 61
32490629 2020
22
Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis. 61
32509239 2020
23
Resistance of aspirin during and after pregnancy: A longitudinal cohort study. 61
31865169 2020
24
The emergent phenomenon of aspirin resistance: insights from genetic association studies. 61
31957546 2020
25
Aspirin Resistance Incidence and Associations Between Aspirin Effect and Outcomes in Cardiac Surgery. 61
31238032 2019
26
Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. 61
30025441 2019
27
Determinants of aspirin resistance in patients with type 2 diabetes. 61
31783142 2019
28
Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2. 61
30989683 2019
29
Correlation of Cardiovascular Risk Factors and Biomarkers With Platelet Reactivity in Coronary Artery Disease. 61
30418226 2019
30
Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. 61
31511539 2019
31
The dilemma of aspirin resistance in obese patients. 61
31660303 2019
32
Aspirin Resistance: Cardiovascular Risk Game Changer. 61
29757761 2019
33
The potential of acetylsalicylic acid and vitamin E in modulating inflammatory cascades in chickens under lipopolysaccharide-induced inflammation. 61
31533824 2019
34
[Network pharmacology-based study on mechanisms of Danhong Injection in treatment of aspirin resistance]. 61
31359682 2019
35
Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. 61
30985534 2019
36
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. 61
30795966 2019
37
Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. 61
31007424 2019
38
Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. 61
31356179 2019
39
Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin. 61
30786253 2019
40
Investigation into the causes of aspirin resistance in healthy dogs. 61
30302763 2019
41
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. 61
30586555 2019
42
Impact of risk factors of ischemic heart disease on the development of acute coronary syndrome, platelet ultrastructure, and aspirin resistance. 61
31860854 2019
43
Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: a single-centre experience. 61
30501653 2019
44
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. 61
30820515 2019
45
Complex roles of the old drug aspirin in cancer chemoprevention and therapy. 61
29855050 2019
46
Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients. 61
31343071 2019
47
Metabolomic Analysis of Platelets of Patients With Aspirin Non-Response. 61
31680941 2019
48
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. 61
30098132 2019
49
Diabetes and Platelet Response to Low-Dose Aspirin. 61
30265320 2018
50
Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal Function, and Angiotensin Receptor Blockers. 61
29996660 2018

Variations for Aspirin Resistance

Expression for Aspirin Resistance

Search GEO for disease gene expression data for Aspirin Resistance.

Pathways for Aspirin Resistance

Pathways related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 P2RY1 ITGB3 ITGA2 APOB
2
Show member pathways
12.55 PTGS2 ITGB3 ITGA2
3
Show member pathways
12.46 P2RY1 ITGB3 ITGA2
4
Show member pathways
12 PTGS2 PTGS1 ITGB3
5
Show member pathways
11.83 PTGS2 PTGS1 APOB
6 11.59 ITGB3 ITGA2
7 11.56 PTGS2 ITGA2
8 11.53 PTGS2 ITGB3
9 11.51 ITGB3 ITGA2
10 11.35 PTGS1 P2RY1 ITGB3 ITGA2
11 11.33 PTGS2 PTGS1
12 11.31 ITGB3 ITGA2
13 11.3 PTGS2 PTGS1
14 11.11 ITGB3 ITGA2
15 10.97 PTGS2 PTGS1
16 10.92 PTGS2 PTGS1
17
Show member pathways
10.89 PTGS2 PTGS1
18 10.78 PTGS2 PTGS1
19 10.73 PTGS2 PTGS1
20 10.63 PTGS1 P2RY1 ITGB3 ITGA2
21 10.54 PTGS2 PTGS1
22 10.33 PTGS2 PTGS1

GO Terms for Aspirin Resistance

Cellular components related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin complex GO:0008305 8.62 ITGB3 ITGA2

Biological processes related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.77 PTGS2 PTGS1 APOB
2 cell-matrix adhesion GO:0007160 9.6 ITGB3 ITGA2
3 response to organic substance GO:0010033 9.58 PTGS2 APOB
4 viral entry into host cell GO:0046718 9.58 ITGB3 ITGA2
5 blood coagulation GO:0007596 9.58 P2RY1 ITGB3 ITGA2
6 cellular oxidant detoxification GO:0098869 9.57 PTGS2 PTGS1
7 cellular response to mechanical stimulus GO:0071260 9.56 PTGS2 ITGA2
8 fatty acid biosynthetic process GO:0006633 9.55 PTGS2 PTGS1
9 cellular response to organic cyclic compound GO:0071407 9.54 P2RY1 ITGA2
10 regulation of blood pressure GO:0008217 9.52 PTGS2 PTGS1
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.51 PTGS2 ITGA2
12 sensory perception of pain GO:0019233 9.49 PTGS2 P2RY1
13 prostaglandin metabolic process GO:0006693 9.48 PTGS2 PTGS1
14 cell adhesion mediated by integrin GO:0033627 9.46 ITGB3 ITGA2
15 positive regulation of smooth muscle contraction GO:0045987 9.43 PTGS2 ITGA2
16 cell-substrate adhesion GO:0031589 9.37 ITGB3 ITGA2
17 cellular response to ATP GO:0071318 9.32 PTGS2 P2RY1
18 prostaglandin biosynthetic process GO:0001516 9.26 PTGS2 PTGS1
19 mesodermal cell differentiation GO:0048333 9.16 ITGB3 ITGA2
20 cyclooxygenase pathway GO:0019371 8.96 PTGS2 PTGS1
21 wound healing GO:0042060 8.8 P2RY1 ITGB3 ITGA2

Molecular functions related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dioxygenase activity GO:0051213 9.26 PTGS2 PTGS1
2 virus receptor activity GO:0001618 9.16 ITGB3 ITGA2
3 peroxidase activity GO:0004601 8.96 PTGS2 PTGS1
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1

Sources for Aspirin Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....